Journal of Manipulative and Physiological Therapeutics
Volume 25, Issue 3 , Pages 168-179 , March 2002

The diet-induced proinflammatory state: A cause of chronic pain and other degenerative diseases?

Received 29 March 2001

References 

  1. Sedgwick A, Willoughby D. Initiation of the inflammatory response and its prevention. In:  Bonta I,  Bray M,  Parnham M editor. Handbook of inflammation, volume 5: the pharmacology of inflammation. New York: Elsevier; 1985;p. 27–47
  2. Cotran R, Kumar V, Robbins S. Robbins pathologic basis of disease. In: 5th ed. Philadelphia: WB Saunders; 1994;p. 1–34 770-1
  3. Kellett J. Acute soft tissue injuries—a review of the literature. Med Sci Sports Exer. 1986;18:489–500
  4. Fries J. Approach to the patient with musculoskeletal disease. In: 19th ed.  Wyngaarden J,  Smith L,  Bennett J editor. Cecil textbook of medicine. Philadelphia: WB Saunders; 1992;p. 1488–1491
  5. McGeer P, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1991;335:1037
  6. Tekin D, Sin BA, Mungan D, Misirligil Z, Yavuzer S. The antioxidative defense in asthma. J Asthma. 2000;37:59–63
  7. Epstein F. Chemokines—Chemotactic cytokines that mediate inflammation. N Eng J Med. 1998;338:436–445
  8. Robbins S. Pathologic basis of disease. Philadelphia: WB Saunders; 1974;
  9. Leslie K. Undesirable inflammatory responses. In:  Thornborough J editors. Inflammation I: pretest key concepts series. volume 3:New York: McGraw-Hill; 1995;p. 121–176
  10. In: Surgeon General's Report on Nutrition and Health. US Department of Health and Human Services. Washington: US Government Printing Office; 1988;p. 2–4 Pub. No. 88-50211
  11. Famighetti R, McGeveran W, Wiesenfeld L, Ellis B, Friedlander M, O'Malley M. The world almanac and book of facts. In: Mahwah (NJ): World Almanac Books; 1997;p. 964
  12. Gerster H. The potential role of lycopene for human health. J Am Coll Nutr. 1997;16:109–126
  13. Linder M. Nutrition and metabolism of vitamins. In: 2nd edition.  Linder M editors. Nutritional biochemistry and metabolism, with clinical implications. New York: Elsevier; 1991;p. 111–189
  14. Block G. Dietary guidelines and the results of food consumption surveys. Am J Clin Nutr. 1991;53:356S–357S
  15. Craig W. Phytochemicals: guardians of our health. J Am Diet Assoc. 1997;97(suppl 2):S199–S204
  16. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991;54:438–463
  17. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(suppl):560S–569S
  18. In:  Willis WD editors. Hyperalgesia and allodynia. New York: Raven Press; 1992;p. 1–11
  19. Fields HL. Pain. New York: McGraw-Hill; 1987;
  20. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses, and pathological pain states. Pain. 1995;63:289–302
  21. In: Progress in Pain Research and Management. Vancouver, British Columbia, Canada, August 17-22, 1996.  Jensen TS,  Turner JA,  Wiesenfeld-Hallin Z editor. Proceedings of the 8th World Congress on Pain. Seattle: IASP Press; 1997;
  22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  23. Salomaa V, Salminen I, Rasi V, Vahtera E, Aro A, Myllyla G. Association of the fatty acid composition of serum phospholipids with hemostatic factors. Aterioscler Thromb Vas Biol. 1997;17:809–813
  24. Meydani M. Nutrition, immune cells, and atherosclerosis. Nutr Rev. 1998;56:S177–S182
  25. Valone F. Platelets. In: 4th ed.  Kelly W,  Harris E,  Ruddy S,  Sledge C editor. Textbook of rheumatology. Philadelphia: WB Saunders; 1993;p. 319–326
  26. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642–1646
  27. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep. 2000;7:169–170
  28. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81:62–68
  29. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al.  Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000;9:119–123
  30. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83:355–358
  31. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998;77:511–515
  32. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114:441–447
  33. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952
  34. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83:112–120
  35. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000;60:4629–4637
  36. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF, et al.  Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?. FASEB J. 2000;14:1499–1507
  37. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 2000;20:2625–2631
  38. Reich R, Martin GR. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins. 1996;51:1–17
  39. Rose DP. Dietary fatty acids and cancer. Am J Clin Nutr. 1997;66(suppl):998S–1003S
  40. Capone SL, Bagga D, Glaspy JA. In: Relationship between omega-3 and omega-6 fatty acid ratios and breast cancer. 13:1997;p. 822–824
  41. Stoll BA. Essential fatty acids, insulin resistance, and breast cancer. Nutr Cancer. 1998;31:72–77
  42. Bougnoux P, Koscielny S, Chajes V, Descamps P, Couet C, Calais G. alpha-Linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer. Br J Cancer. 1994;70:330–334
  43. Mackie BS, Mackie LE, Curtin LD, Bourne DJ. Melanoma and dietary lipids. Nutr Cancer. 1987;9:220–226
  44. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos N, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. Cancer. 1998;82:395–402
  45. Gonzalez MJ. Fish oil, lipid peroxidation and mammary tumor growth. J Am Coll Nutr. 1995;14:325–335
  46. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709–5714
  47. Sugaya K, Uz T, Kumar V, Manev H. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol. 2000;82:85–94
  48. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral. Brain Res. 1999;830:226–236
  49. Ho L, Pieroni C, Winger D, Purohuit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999;57:295–303
  50. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 1998;87:319–324
  51. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, et al.  Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 1999;53:1495–1498
  52. McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging. 2000;17:1–11
  53. Hull M, Lieb K, Fiebich BL. Anti-inflammatory drugs: a hope for Alzheimer's disease?. Expert Opin Investig Drugs. 2000;9:671–683
  54. Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur J Neurosci. 2000;12:1900–1912
  55. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. 2000;18:383–399
  56. Kalmijn S, Feskens EJM, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol. 1997;145:33–41
  57. Sinclair H. The relative importance of essential fatty acids of the linoleic and linolenic families: studies with an Eskimo diet. Prog Lipid Res. 1981;20:897–899
  58. Nettleton J. Omega-3 fatty acids and health. In: New York: Chapman & Hall; 1995;p. 67–73
  59. Calder PC. Dietary fatty acids and the immune system. Nutr Rev. 1998;(II):S70–S83
  60. Rudin D. The dominant diseases of modernized societies as omega-3 fatty essential fatty acid deficiency syndrome: substrate beriberi. Med Hypoth. 1982;8:17–47
  61. Fernandes G, Venkatraman J. Role of omega-3 fatty acids in health and disease. Nutr Res. 1993;13(suppl 1):S19–S45
  62. Simopoulos AP, Robinson J. The omega plan. In: New York: Harper Collins; 1998;p. 25; 133
  63. Calder PC. n-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab. 1997;41:203–234
  64. Myedani S. Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Nutrition. 1996;12:S8–S14
  65. United States Department of Agriculture USDA . USDA food pyramid. available at http://www.nalusda.gov/fnic/Fpyr/pyramid.htmlJune, 1998; Accessed
  66. Siguel EN, Lerman RH. Role of essential fatty acids: dangers in the US Department of Agriculture dietary recommendations (pyramid) and low-fat diets. Am J Clin Nutr. 1994;60:973–974
  67. Connor S, Connor W. Are fish oils beneficial in the prevention and treatment of coronary artery disease?. Am J Clin Nutr. 1997;66(suppl):1020S–1031S
  68. Chin J. Marine oils and cardiovascular reactivity. Prost Leuk Essent Fatty Acids. 1994;50:211–222
  69. Kremer J. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. Rheum Dis Clin N Am. 1991;17:391–402
  70. Sperling R. Dietary omega-3 fatty acids: effects on lipid mediators of inflammation and rheumatoid arthritis. Rheum Dis Clin N Am. 1991;17:373–389
  71. Linder M. Nutrition and metabolism of fats. In: 2nd ed.  Linder M editors. Nutritional biochemistry and metabolism: with clinical implications. New York: Elsevier; 1991;p. 51–85
  72. Pike M. Antiinflammatory effects of dietary lipid modification. J Rhematol. 1989;16:718–720
  73. Saunders T, Younger K. The effect of dietary supplements of n-3 polyunsaturated fatty acids on the fatty acid composition of platelets and plasma choline phophoglycerides. Brit J Nutr. 1981;45:613–618
  74. Salmon J, Terano T. Supplementation of the diet with eicosapentaenoic acid: a possible approach to the treatment of thrombosis and inflammation. Proc Nutr Soc. 1985;44:385–389
  75. Bucci L. Nutrition applied to injury rehabilitation and sports medicine. In: Boca Raton (FL): CRC Press; 1995;p. 53–58 205-8
  76. Broughton K, Johnson C, Pace B, Liebman M, Kleppinger K. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leuktorine production. Am J Clin Nutr. 1997;65:1011–1017
  77. Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr. 2000;71(Suppl 1):349S–351S
  78. Saynor R, Gillott T. Changes in blood lipis and fibrinogen with a note on safety in a long-term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids. 1992;27:533–538
  79. Gaziano JM. Antioxidants in cardiovascular disease: randomized trials. Nutrition. 1996;12:583–588
  80. Kjeldsen-Kragh J, Haugen M, Borchgrevink C, Laerum E, Eek M, Mowinkel P, et al.  Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet. 1991;338:899–902
  81. Kjeldsen-Kragh J. Rheumatoid arthritis treated with vegetarian diets. Am J Clin Nutr. 1999;70(suppl):594S–600S
  82. Nestle M, Bal D, Birt D, et al.  Guidelines on diet, nutrition, and cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. American Cancer Society 1996 Advisory Committee on Diet, Nutrition, and Cancer Prevention. CA Cancer J Clin. 1996;46:325–341
  83. Lampe JW. Health effects of vegetables and fruits: assessing mechanisms of action in human experimental studies. Am J Clin Nutr. 1999;70(suppl):475S–490S
  84. Steinmetz K, Potter J. Vegetables, fruit, and cancer prevention: a review. J AM Diet Assoc. 1996;96:1027–1039
  85. Hasler C. Functional foods: the western perspective. Nutr Rev. 1996;54(suppl):S6–S10
  86. Floyd R. Basic free radical biochemistry. In:  Yu B editors. Free radicals in aging. Boca Raton (FL): CRC Press; 1993;p. 39–55
  87. Halliwell B, Evans P, Kaur H, Aruoma O. Free radicals, tissue injury, and human disease: a potential of therapeutic use of antioxidants?. In:  Kinney J,  Tucker H editor. Organ metabolism and nutrition: ideas for future critical care. New York: Raven Press; 1994;p. 425–445
  88. Freeman B, Crapo J. Biology of disease: free radicals and tissue injury. Lab Invest. 1982;47:412–426
  89. Block G. The data support a role for antioxidants in reducing cancer risk. Nutr Rev. 1992;50:207–213
  90. Allen R. Free radicals and differentiation: the interrelationship of development and aging. In:  Yu B editors. Free radicals in aging. Boca Raton (FL): CRC Press; 1993;p. 11–37
  91. Demopoulos H, Pietronigro D, Seligman M. The development of secondary pathology with free radical reactions as threshold mechanism. J Am Coll Toxico. 1983;2:173–184
  92. Kremer J. Nutrition and rheumatic diseases. In: 4th ed.  Kelley W,  Harris E,  Ruddy S,  Sledge C editor. Textbook of rheumatology. Philadelphia: WB Saunders; 1993;p. 483–497
  93. Cranton E, Frackelton J. Free-radical pathology in age-associated disease: treatment with EDTA chelation, nutrition and antioxidants. J Hol Med. 1984;6:6–37
  94. DelMaestro R. An approach to free radicals in medicine and biology. Acta Physiol Scand. 1980;492(suppl):153–167
  95. Maxwell SR. Prospects for the use of antioxidant therapies. Drugs. 1995;49:345–361
  96. Conner E, Grisham M. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12:274–277
  97. Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183–1186
  98. van de Vijver LPL, Kardinaal AFM, Grobbee DC, Princen HMG, van Poppel G. Lipoprotein oxidation, antioxidants and cardiovascular risk: epidemiologic evidence. Prost Leuk Essen Fat Acids. 1997;57:479–487
  99. Mosca L, Rubenfire M, Mandel C, Rock C, Tarshis T, Tsai A, et al.  Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol. 1997;30:392–399
  100. Diaz M, Frei B, Vita J, Keaney J. Antioxidants and atherosclerotic heart disease. N Eng J Med. 1997;337:408–416
  101. Cutler R. Antioxidants and aging. Am J Clin Nutr. 1991;53:373S–379S
  102. Marsden C. Parkinson's disease. Lancet. 1990;335:948–952
  103. Mitsumoto H, Chad D, Pioro E. Amyotrophic lateral sclerosis. In: Philadelphia: FA Davis; 1998;p. 197–225
  104. Schmidt K. Antioxidant vitamins and beta-carotene: effects on immunocompetence. Am J Clin Nutr. 1991;53:383S–385S
  105. Varma S. Scientific basis for medical therapy of cataracts by antioxidants. Am J Clin Nutr. 1991;53:335S–345S
  106. Weisburger J. Nutrition approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr. 1991;53:226S–237S
  107. Flagg E, Coates R, Greenburg R. Epidemiologic studies of antioxidants and cancer in humans. J Am Col Nutr. 1995;14:419–427
  108. Yasuma T, Arai K, Suzuki F. Age-related phenomena in the lumbar intervertebral discs: lipofuscin and amyloid deposition. Spine. 1992;17:1194–1198
  109. Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskeletal Pain. 1997;5:5–15
  110. Sen CK. Oxidants and antioxidants in exercise. J Appl Physiol. 1995;79:675–686
  111. Brodsky I, Devlin J. Hormone and nutrient interactions. In: 8th ed.  Shils M,  Olson J,  Shike M editor. Modern nutrition in health and disease. Philadelphia: WB Saunders; 1994;p. 603–622
  112. Chow C. Nutritional influence on cellular antioxidant defense systems. Am J Clin Nutr. 1979;32:1066–1081
  113. Broquist H. Buthionine sulfoximine, an experimetal tool to induce glutathione deficiency: elucidation of glutathione and ascorbate in their role as antioxidants. Nutr Rev. 1992;50:110–111
  114. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev. 1994;52:253–265
  115. Linder M. Nutrition and metabolism of the trace elements. In: 2nd ed.  Linder M editors. Nutritional biochemistry and metabolism with clinical implications. New York: Elsevier; 1991;p. 215–276
  116. Nielsen F. Ultratrace minerals. In: 8th ed.  Shils M,  Olson J,  Shike M editor. Modern nutrition in health and disease. Philadelphia: WB Saunders; 1994;p. 269–286
  117. Pangborn J. Flow chart—amino acid metabolism. Lisle (IL): Bionostics; 1981;
  118. Wiggins D. Intermediate metabolism. Milwaukee (WI): P-L Biochemicals; 1982;
  119. Havsteen B. Flavonoids, a class of natural products of high pharmacologic potency. Biochem Pharmacol. 1983;32:1141–1148
  120. Mascolo N, Pinto A, Capasso F. Flavonoids, leucocyte migration and eicosanoids. J Pharm Pharmacol. 1988;40:293–295
  121. Machiex JJ, Fleuriet A, Billot J. Fruit phenolics. In: Boca Raton (FL): CRC Press; 1990;p. 272–273
  122. Combs G. The vitamins: fundamental aspects in nutrition and health. In: New York: Academic Press; 1992;p. 425
  123. Pain in America. A research report prepared for: Merck. Ogilvy Public Relations Worldwide; April, 2000;
  124. Mooney V. Where is the pain coming from?. Spine. 1987;12:754–759
  125. Wall P. Introduction to the edition after this one. In: 3rd ed.  Wall P,  Melzack R editor. Textbook of pain. New York: Churchill Livingstone; 1994;p. 1–7
  126. Franson R, Saal J, Saal J. Human disc phospholipase A2 is inflammatory. Spine. 1992;17:S129–S132
  127. Montgomery R, Conway T, Spector A. Biochemistry: a case oriented approach. In: 5th ed. St. Louis: Mosby; 1990;p. 519–534
  128. Saal J, Franson R, Dobrow R, Saal J, White A, Goldthwaite N. High levels of inflammatory phopholipase A-2 activity in lumbar disc herniations. Spine. 1990;15:674–678
  129. Sierkerka J. Nutrition and biochemistry of the intervertebral disc. Chiropr Technique. 1991;3:116–121
  130. Seljeflot I, Johansen O, Arnesen H, Eggesbo JB, Westvik AB, Kierulf P. Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids. Thromb Haemost. 1999;81:566–567

☆ Submit reprint requests to: David R. Seaman, DC, MS, DABCN, 4326 Market St, #110, Wilmington, NC 28403, USA.

PII: S0161-4754(02)18454-5

doi: 10.1067/mmt.2002.122324

Journal of Manipulative and Physiological Therapeutics
Volume 25, Issue 3 , Pages 168-179 , March 2002

Article Tools

* Image Usage & Resolution